<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03636750</url>
  </required_header>
  <id_info>
    <org_study_id>HB002.1T-01</org_study_id>
    <nct_id>NCT03636750</nct_id>
  </id_info>
  <brief_title>A Study of Injection HB002.1T in Subjects With Solid Tumor</brief_title>
  <official_title>A Phase 1, Safety, Tolerability and Pharmacokinetic Profile Study of Intravenous Injections of HB002.1T (a Vascular Endothelial Growth Factor Receptor Decoy) in Subjects With Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huabo Biopharm Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huabo Biopharm Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic&#xD;
      profile of HB002.1T, a human immunoglobulin Fc fusion protein containing domain 2 and&#xD;
      flanking sequence of vascular endothelial growth factor (VEGF) receptor-1 in subjects with&#xD;
      solid tumor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2018</start_date>
  <completion_date type="Actual">March 21, 2020</completion_date>
  <primary_completion_date type="Actual">February 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT) defined as grade 3 or higher National Cancer Institute - Common Terminology Criteria (NCI-CTC) toxicities</measure>
    <time_frame>21 days after the first treatment</time_frame>
    <description>Dose-limiting toxicity (DLT) defined as grade 3 or higher National Cancer Institute - Common Terminology Criteria (NCI-CTC) toxicities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Titer and detection rate of anti drug antibody</measure>
    <time_frame>1,8,15,and 21 days after the first treatment, at the end of each treatment cycle (cycle 1 is 21 days, cycle 2 to 5 is 14 days) , and and up to 28 days after last treatment</time_frame>
    <description>Titer and detection rate of anti drug antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>7 days before first treatment, at the end of treatment cycle 4 and cycle 5 (cycle 1 is 21 days, cycle 2 to 5 is 14 days)</time_frame>
    <description>Objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>7 days before first treatment, at the end of treatment cycle 4 and cycle 5 (cycle 1 is 21 days, cycle 2 to 5 is 14 days)</time_frame>
    <description>Disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Computed Tomography</measure>
    <time_frame>7 days before first treatment, at the end of treatment cycle 4 and cycle 5 (cycle 1 is 21 days, cycle 2 to 5 is 14 days)</time_frame>
    <description>Computed tomography examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration</measure>
    <time_frame>1,8,15,and 21 days after the first treatment, at the end of each treatment cycle (cycle 1 is 21 days, cycle 2 to 5 is 14 days) , and and up to 28 days after last treatment</time_frame>
    <description>Peak plasma concentration of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC)</measure>
    <time_frame>1,8,15,and 21 days after the first treatment, at the end of each treatment cycle (cycle 1 is 21 days, cycle 2 to 5 is 14 days) , and and up to 28 days after last treatment</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of patients</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>HB002.1T 2mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 2mg/kg dose of HB002.1T via intravenous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB002.1T 4mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 4mg/kg dose of HB002.1T via intravenous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB002.1T 8mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 8mg/kg dose of HB002.1T via intravenous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB002.1T 12mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 12mg/kg dose of HB002.1T via intravenous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB002.1T 16mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 16mg/kg dose of HB002.1T via intravenous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB002.1T 20mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 20mg/kg dose of HB002.1T via intravenous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB002.1T</intervention_name>
    <description>HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy</description>
    <arm_group_label>HB002.1T 12mg/kg</arm_group_label>
    <arm_group_label>HB002.1T 16mg/kg</arm_group_label>
    <arm_group_label>HB002.1T 20mg/kg</arm_group_label>
    <arm_group_label>HB002.1T 2mg/kg</arm_group_label>
    <arm_group_label>HB002.1T 4mg/kg</arm_group_label>
    <arm_group_label>HB002.1T 8mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 75 years old of either gender;&#xD;
&#xD;
          -  Standard treatment failure, or no standard treatment, or subjects with advanced&#xD;
             malignant solid tumors diagnosed by histology or cytology that are not suitable for&#xD;
             standard treatment at this stage; there is no limit to the number of treatment options&#xD;
             before enrollment;&#xD;
&#xD;
          -  Anti-tumor therapy such as radiotherapy, chemotherapy, targeted therapy, endocrine&#xD;
             therapy or immunotherapy was not received within 4 weeks before the first treatment of&#xD;
             HB002.1T. Mitomycin and nitrosourea were administered for 6 weeks, fluorouracil Oral&#xD;
             medications such as tega, capecitabine for at least 2 weeks from the last dose;&#xD;
&#xD;
          -  At least one evaluable lesion according to RECIST 1.1;&#xD;
&#xD;
          -  ECOG(Eastern Cooperative Oncology Group) performance status 0 or 1&#xD;
&#xD;
          -  The expected survival period is not less than 12 weeks;&#xD;
&#xD;
          -  The organ function indicated by the following laboratory indicators must be met:&#xD;
&#xD;
               1. No growth factor support therapy within 14 days, absolute neutrophil count&#xD;
                  ≥1.5E+9/L;&#xD;
&#xD;
               2. No transfusion support therapy or growth factor therapy within 14 days ,&#xD;
                  hemoglobin ≥ 90g/L;&#xD;
&#xD;
               3. Platelet count ≥ 100E+9/L;&#xD;
&#xD;
               4. Serum creatinine ≤ 1.5 × upper limit of normal (ULN), or creatinine clearance ≥&#xD;
                  60mL / min (serum creatinine &gt; 1.5 × ULN);&#xD;
&#xD;
               5. Total bilirubin ≤ 1.5 × ULN;&#xD;
&#xD;
               6. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT)&#xD;
                  concentrations ≤ 2.5 × ULN, or when elevated due to tumor liver metastasis, ALT&#xD;
                  and AST ≤ 5 × ULN as judged by the investigator;&#xD;
&#xD;
               7. Electrolyte: blood potassium ≥ 3.0 mmol/L; blood calcium ≥ 2.0 mmol/L;&#xD;
&#xD;
               8. Prothrombin time (PT) ≤ 1.2 × ULN;&#xD;
&#xD;
               9. Partial promotion prothrombin time (APTT) ≤ 1.2 × ULN;&#xD;
&#xD;
              10. Urine test paper test results show that urine protein &lt; 1 +, if ≥ 1 +, need to&#xD;
                  meet the 24-hour urine protein content &lt;1g.&#xD;
&#xD;
          -  The toxicity of previous treatment has been restored to NCI CTCAE ≤ 1 (except for hair&#xD;
             loss);&#xD;
&#xD;
          -  Women and men of childbearing age must agree to take effective contraceptive measures&#xD;
             after signing informed consent, during the study period and within 3 months after the&#xD;
             last dose of HB002.1T, and the results of the pregnancy test for women of childbearing&#xD;
             age must be negative;&#xD;
&#xD;
          -  Subjects must voluntarily sign written informed consent;&#xD;
&#xD;
          -  Subjects are able to communicate well with the investigator and are able to comply&#xD;
             with research regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with confirmed active central nervous system metastasis and/or cancerous&#xD;
             meningitis; but patients with central nervous system metastases who have received&#xD;
             treatment and achieved clinical stability for 3 months before starting the study can&#xD;
             be enrolled;&#xD;
&#xD;
          -  A history of infection with human immunodeficiency virus, or other acquired,&#xD;
             congenital disease, or history of organ transplantation;&#xD;
&#xD;
          -  Active hepatitis B patients (viral titer is above the upper limit of detection); or&#xD;
             hepatitis C virus infection;&#xD;
&#xD;
          -  Subjects who have previously been allergic to macromolecular protein&#xD;
             preparations/monoclonal antibodies, or known to be allergic to any of the test drug&#xD;
             components or excipients;&#xD;
&#xD;
          -  Those who have received other clinical trial drugs within 4 weeks before the first&#xD;
             treatment of HB002.1T;&#xD;
&#xD;
          -  Those who have undergone major surgery within 4 weeks prior to screening;&#xD;
&#xD;
          -  Minor surgical procedures (including catheterization, no peripheral venous puncture&#xD;
             central catheterization) within 2 days prior to screening; venous puncture center&#xD;
             catheterization);&#xD;
&#xD;
          -  Patients with systolic blood pressure ≥140mmHg and/or diastolic blood pressure or&#xD;
             diastolic blood pressure ≥90mmHg after antihypertensive treatment (one&#xD;
             antihypertensive drug is allowed in the baseline period, and the compound preparation&#xD;
             is recognized as two);&#xD;
&#xD;
          -  The subject has an active infection or during the screening period, the unexplained&#xD;
             fever occurs before the first dose &gt; 38.5 °C;&#xD;
&#xD;
          -  Those who have had hemoptysis within 4 weeks before screening (defined as coughing&#xD;
             with ≥1 teaspoon of blood), but do not rule out cough only with sputum or small blood&#xD;
             clot;&#xD;
&#xD;
          -  Subjects suffering from the following serious complications:&#xD;
&#xD;
               1. Unstable angina and/or congestive heart failure or vascular disease requiring&#xD;
                  hospitalization within 12 months (eg, aortic aneurysm peripheral thrombectomy),&#xD;
                  or vascular disease (eg, aorta requiring surgical repair) Peripheral static&#xD;
                  thrombus), other heart damage that the investigator judges is not suitable for&#xD;
                  clinical trials (eg, poorly controlled arrhythmias, muscle infarction, etc.);&#xD;
&#xD;
               2. Prior arterial thromboembolic events, venous thrombosis above the venous&#xD;
                  thrombosis of grade 3 or higher in NCI CTCAE, transient ischemic attack (TIA),&#xD;
                  cerebral vascular accident (CVA), transmural Myocardial infarction), transmural&#xD;
                  myocardial infarction, myocardial infarction (MI), hypertensive crisis or&#xD;
                  encephalopathy; hypertensive crisis or encephalopathy; ), hypertensive crisis or&#xD;
                  encephalopathy;&#xD;
&#xD;
               3. Previous or current persistent fulminant hemorrhagic disease;&#xD;
&#xD;
               4. Chronic Obstructive Pulmonary Disease (COPD) or other respiratory illness&#xD;
                  requiring hospitalization within 4 weeks prior to screening;&#xD;
&#xD;
               5. History of abdominal hernia, gastrointestinal perforation abscess or acute&#xD;
                  bleeding in the first 6 months prior to screening;&#xD;
&#xD;
               6. Esophageal varices, unhealed wounds or fractures within 6 months prior to&#xD;
                  screening;&#xD;
&#xD;
               7. Dominant jaundice and/or caused by abnormal liver function&#xD;
&#xD;
          -  Subjects who are in use of warfarin, heparin aspirin (&gt;325 mg/day) or other drugs&#xD;
             known to inhibit platelet function within 10 days prior to the first study treatment;&#xD;
&#xD;
          -  Subjects receiving dipyridamole, ticlopidine, clopidogrel or cilostazol treatment;&#xD;
&#xD;
          -  Subjects with a clear history of neurological or dysfunction, such as poor adherence&#xD;
             to epilepsy;&#xD;
&#xD;
          -  Pregnant or nursing women;&#xD;
&#xD;
          -  Any other reasons assessed by the investigator that are not suitable for participation&#xD;
             in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200123</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

